By Investing Tricks : Sanofi's (NYSE: SNY ) revenues are distributed through three major segments and a large chunk is attributable to the pharmaceutical segment; 85% of revenues are attributed to the pharmaceutical segment. More than half the pharmaceutical revenues are drawn from the US and ...
By Long Term Bio : Orexigen Therapeutics (NASDAQ: OREX ) received FDA approval for their obesity drug Contrave on September 10th, 2014. The FDA has finally determined that Contrave is a safe obesity drug to give to patients to help reduce their weight. Orexigen Therapeutics has been struggling to
By Sharon di Stefano : Pharmaceutical companies are adept at rolling out new classes of drugs, despite potential harmful side effects, and Eli Lilly and Co. (NYSE: LLY ) is no exception. Just recently, Lilly began selling Jardiance, a once-daily tablet for Type 2 diabetics, a 'flozin', with an ...
By Spencer Osborne : Novo Nordisk (NYSE: NVO ) received good news earlier this week in its quest to get an obesity indication for its drug Saxenda. The drug is a different
The FDA's Endocrinologic and Metabolic Drugs Advisory Committee concludes that Novo Nordisk's ( NVO +1.8% ) obesity drug Saxenda (liraglutide) is safe and effective enough to warrant approval . Post your comment!
By KLLJ Investments : It has been some time since I have written an article covering Arena Pharmaceuticals (NASDAQ: ARNA ), and I have recently received inquiries asking if I still believe in the company and the prospects for its lead drug, Belviq. Given the stock is hitting 52-week lows, despite
The FDA's Endocrinologic and Metabolic Drugs Advisory Committee meets this Thursday to discuss Novo Nordisk's ( NVO +2.3% ) NDA for Saxenda ( liraglutide ) as an adjunct to a reduced-calorie diet and increased physical activity for chronic
inflammatory diseases space after discontinuing anti-IL-20 for the treatment of rheumatoid arthritis, Novo Nordisk (NYSE: NVO ) decides to discontinue its R&D efforts in the area. EVP and CSO Mads Krogsgaard Thomsen says, "The discontinuation of
they're even busier handing out insulin with the other. Not-so-famously, Denmark is also home to Novo Nordisk (NYSE: NVO ), the world's largest player in the diabetes care market. With the share price up more than 20% year-to-date, Novo
risks to an investment in China Biologic, given that the plasma space is home to Baxter (NYSE: BAX ) and Novo Nordisk (NYSE: NVO ), which market internationally ADVATE and NovoSeven, NovoEight and NovoThirteen, respectively. Nevertheless, the latest